PAIN
MCID: PNS012
MIFTS: 63

Paine Syndrome (PAIN)

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Paine Syndrome

MalaCards integrated aliases for Paine Syndrome:

Name: Paine Syndrome 57 19 71
Pain Disorder 11 53 14 71
Pain 5 41 16
Microcephaly with Spastic Diplegia 57 19
Pain Syndrome 14

Characteristics:


Inheritance:

X-linked 57

Classifications:



External Ids:

Disease Ontology 11 DOID:0060164
OMIM® 57 311400
ICD10 31 R52 R52.9
MedGen 40 C1412041
UMLS 71 C0391976 C1412041

Summaries for Paine Syndrome

MedlinePlus: 41 Pain is a signal in your nervous system that something may be wrong. It is an unpleasant feeling, such as a prick, tingle, sting, burn, or ache. Pain may be sharp or dull. It may come and go, or it may be constant. You may feel pain in one area of your body, such as your back, abdomen, chest, pelvis, or you may feel pain all over. Pain can be helpful in diagnosing a problem. If you never felt pain, you might seriously hurt yourself without knowing it, or you might not realize you have a medical problem that needs treatment. There are two types of pain: acute and chronic. Acute pain usually comes on suddenly, because of a disease, injury, or inflammation. It can often be diagnosed and treated. It usually goes away, though sometimes it can turn into chronic pain. Chronic pain lasts for a long time, and can cause severe problems. Pain is not always curable, but there are many ways to treat it. Treatment depends on the cause and type of pain. There are drug treatments, including pain relievers. There are also non-drug treatments, such as acupuncture, physical therapy, and sometimes surgery. NIH: National Institute of Neurological Disorders and Stroke

MalaCards based summary: Paine Syndrome, also known as pain disorder, is related to paroxysmal extreme pain disorder and indifference to pain, congenital, autosomal recessive. An important gene associated with Paine Syndrome is HFE (Homeostatic Iron Regulator), and among its related pathways/superpathways are Cardiac conduction and G-Beta Gamma Signaling. The drugs Dinoprostone and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include dorsal root ganglion, spinal cord and breast, and related phenotypes are microcephaly and spastic diplegia

GARD: 19 Mental retardation, microcephaly, spastic diplegia, seizures, and mild aminoaciduria are the principal features. Seemanova syndrome 1 and Paine syndrome are considered as variants of the same entity termed Paine-Seemanova syndrome.

Disease Ontology: 11 A somatoform disorder that involves chronic pain in one or more areas, and is thought to be caused by psychological stress.

More information from OMIM: 311400

Related Diseases for Paine Syndrome

Diseases in the Chronic Pain family:

Paine Syndrome Central Pain Syndrome

Diseases related to Paine Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 4315)
# Related Disease Score Top Affiliating Genes
1 paroxysmal extreme pain disorder 32.9 TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
2 indifference to pain, congenital, autosomal recessive 32.9 SCN9A SCN11A SCN10A
3 myofascial pain syndrome 32.7 TRPV1 TAC1 P2RX3 NGF CALCA
4 episodic pain syndrome, familial, 3 32.7 TRPA1 SCN9A SCN3A SCN11A SCN10A
5 episodic pain syndrome, familial, 1 32.7 TRPV1 TRPA1 SCN9A SCN11A SCN10A
6 complex regional pain syndrome 32.6 TRPV1 TRPA1 TAC1 SCN9A SCN11A SCN10A
7 familial episodic pain syndrome 32.6 TRPV1 TRPA1 SCN9A SCN11A SCN10A
8 neuropathy, hereditary sensory and autonomic, type vii 32.6 SCN9A SCN11A
9 episodic pain syndrome, familial, 2 32.5 TRPA1 SCN9A SCN4A SCN3A SCN11A SCN10A
10 reflex sympathetic dystrophy 32.5 TRPV1 TAC1 SCN9A SCN11A NGF CALCA
11 causalgia 32.4 TRPV1 TAC1 SCN9A SCN10A NGF CALCA
12 pain agnosia 32.2 TRPV1 TRPA1 TAC1 SCN9A SCN11A SCN10A
13 glossopharyngeal neuralgia 32.1 TRPV1 TAC1 SCN9A P2RX3 CALCA
14 plantar fasciitis 32.1 TAC1 CALCA
15 hereditary sensory neuropathy 32.0 SCN9A SCN11A NGF
16 neuropathy 32.0 SCN9A SCN11A SCN10A NGF GJB1
17 epicondylitis 32.0 TAC1 COL5A1 CALCA
18 bursitis 31.9 TAC1 CALCA
19 frozen shoulder 31.8 TAC1 CALCA
20 lateral medullary syndrome 31.8 TAC1 CALCA
21 alcoholic neuropathy 31.7 TRPA1 P2RX3
22 acute cystitis 31.6 TRPV1 NGF
23 hirschsprung disease 1 31.6 TAC1 NGF GAL CALCA
24 nerve compression syndrome 31.6 TRPV1 TAC1 NGF CALCA
25 opioid abuse 31.5 TAC1 PNOC OPRM1
26 peripheral nervous system disease 31.5 TRPV1 TRPA1 TAC1 SCN9A SCN4A SCN3A
27 lesion of sciatic nerve 31.5 TRPV1 NGF
28 neuroma 31.5 TRPV1 SCN10A NGF CALCA
29 urethral syndrome 31.5 TAC1 P2RX3 NGF
30 hyperhidrosis, gustatory 31.5 TRPV1 TRPA1 TAC1
31 cluster headache 31.4 PNOC CALCA
32 sodium channelopathy-related small fiber neuropathy 31.4 SCN9A SCN11A SCN10A
33 interval angle-closure glaucoma 31.4 TAC1 CALCA
34 familial hemiplegic migraine 31.4 SCN9A P2RX3 OPRM1 CALCA
35 bowel dysfunction 31.3 TRPV1 TAC1 OPRM1 CALCA
36 chronic pain 31.3 SCN9A P2RX3 OPRM1
37 erythromelalgia 31.3 TRPV1 TRPA1 TAC1 SCN9A SCN4A SCN3A
38 trigeminal neuralgia 31.2 TRPV1 TRPA1 TAC1 SCN9A SCN3A SCN11A
39 mononeuropathy 31.1 TRPV1 TAC1 NGF GJB1 GAL CALCA
40 diabetic polyneuropathy 31.0 TRPV1 TAC1 SCN9A SCN10A NGF CALCA
41 taylor's syndrome 31.0 TAC1 CALCA
42 horner's syndrome 30.9 NGF CALCA
43 migraine with aura 30.8 TAC1 SCN9A OPRM1 CALCA
44 brugada syndrome 30.8 SCN9A SCN4A SCN3A SCN11A SCN10A
45 neurogenic arthropathy 30.7 SCN9A NGF CALCA
46 fibromyalgia 30.6 SCN9A PNOC P2RX3 OPRM1 NGF CALCA
47 overactive bladder syndrome 30.6 P2RX3 NGF
48 chronic cystitis 30.6 TRPV1 TAC1 P2RX3 NGF
49 graves disease 1 30.4 SCN4A CALCA
50 paralytic ileus 30.4 TAC1 CALCA

Graphical network of the top 20 diseases related to Paine Syndrome:



Diseases related to Paine Syndrome

Symptoms & Phenotypes for Paine Syndrome

Human phenotypes related to Paine Syndrome:

30
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 microcephaly 30 HP:0000252
2 spastic diplegia 30 HP:0001264
3 olivopontocerebellar hypoplasia 30 HP:0006955
4 generalized myoclonic seizure 30 HP:0002123

Symptoms via clinical synopsis from OMIM®:

57 (Updated 08-Dec-2022)
Head:
microcephaly
hypoplasia of cerebellum, inferior olives and pons

Lab:
variable elevated spinal fluid amino acids

Neuro:
spastic diplegia
myoclonic seizures
absent abdominal reflexes

Clinical features from OMIM®:

311400 (Updated 08-Dec-2022)

MGI Mouse Phenotypes related to Paine Syndrome:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.1 CALCA GAL GJB1 HFE NGF OAT
2 normal MP:0002873 10.07 CALCA COL5A1 HFE NGF OAT OPRM1
3 growth/size/body region MP:0005378 9.97 COL5A1 GAL GJB1 HFE NGF OAT
4 behavior/neurological MP:0005386 9.91 CALCA GAL GJB1 HFE NGF OAT
5 no phenotypic analysis MP:0003012 9.87 HFE NGF OPRM1 SCN10A SCN3A TRPA1
6 integument MP:0010771 9.47 CALCA COL5A1 GAL NGF OAT OPRM1

Drugs & Therapeutics for Paine Syndrome

Drugs for Paine Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 257)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dinoprostone Approved Phase 4 363-24-6, 7448-03-5 5280360
2
Dexmedetomidine Approved, Experimental, Vet_approved Phase 4 86347-14-0, 113775-47-6 68602 5311068
3
Cycloserine Approved Phase 4 68-41-7 6234
4
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
5
Ethanol Approved Phase 4 64-17-5 702
6
Amitriptyline Approved Phase 4 50-48-6 2160
7
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
8
Ibuprofen Approved Phase 4 15687-27-1 3672
9
Cyclobenzaprine Approved Phase 4 303-53-7 2895
10
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
11
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
12
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
13
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
14
Heparin, bovine Approved, Investigational, Withdrawn Phase 4 9005-49-6 22833565 9812414 772
15
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
16
Sodium citrate Approved, Investigational Phase 4 68-04-2 23431961
17
Sildenafil Approved, Investigational Phase 4 139755-83-2, 171599-83-0 5212 135398744
18
Cholecalciferol Approved, Nutraceutical, Vet_approved Phase 4 67-97-0, 1406-16-2 5280795 10883523
19
Ascorbic acid Approved, Nutraceutical Phase 4 50-81-7 54676860 54670067 5785
20
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 22737-96-8, 68-26-8 5280382 445354
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
22
Mosapride Investigational Phase 4 112885-41-3 119584
23
Dexetimide Withdrawn Phase 4 21888-98-2 30843
24 Trace Elements Phase 4
25 Micronutrients Phase 4
26 Calciferol Phase 4
27 Psychotropic Drugs Phase 4
28 Analgesics, Opioid Phase 4
29 Anticonvulsants Phase 4
30 Dexamethasone 21-phosphate Phase 4
31 HIV Protease Inhibitors Phase 4
32 Taxane Phase 4 108169
33
protease inhibitors Phase 4
34 Excitatory Amino Acid Antagonists Phase 4
35 Vitamins Phase 4
36 Antioxidants Phase 4
37 Anti-Anxiety Agents Phase 4
38 Anti-Ulcer Agents Phase 4
39 Antacids Phase 4
40 Proton Pump Inhibitors Phase 4
41 Serotonin Receptor Agonists Phase 4
42 Hypnotics and Sedatives Phase 4
43 Antimetabolites Phase 4
44 Antitubercular Agents Phase 4
45 Antibiotics, Antitubercular Phase 4
46
Ketorolac Tromethamine Phase 4
47 Antidepressive Agents, Tricyclic Phase 4
48 Potassium phosphate Phase 4
49
abobotulinumtoxinA Phase 4
50 Botulinum Toxins, Type A Phase 4

Interventional clinical trials:

(show top 50) (show all 780)
# Name Status NCT ID Phase Drugs
1 CT-guided Ganglion Impar Block for Management of Phantom Rectal Pain Syndrome Unknown status NCT03694639 Phase 4
2 The Effect of Preventional Drug Therapy on Pain Regulation Mechanisms Among Spinal Cord Injury Patients Who Have Yet to Develop Central Pain Unknown status NCT03748290 Phase 4 Pregabalin;Placebo Oral Tablet
3 The Immune and Clinical Impacts of Vitamin D in Patients With Chronic Musculo-skeletal Pain Unknown status NCT01417923 Phase 4 vitamin D
4 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
5 A Multi-Centre Randomised Study Comparing Tapering Low Dose Dexamethasone to Other Standard of Care Therapies for Taxane- Associated Pain Syndrome (TAPS) in Breast Cancer Patients (OTT 17-02 REaCT-TAPS) Completed NCT03348696 Phase 4 Dexamethasone tapering dose;Dexamethasone physician choice
6 Cortisone Injection vs Trigger Point Dry Needling Fin the Treatment of Greater Trochanter Pain Syndrome: A Pilot Study Completed NCT02639039 Phase 4 Cortisone Injection
7 A Comparative Study of Lansoprazole and Mosapride for Functional Dyspepsia: Focus on Difference Between Epigastric Pain Syndrome and Postprandial Distress Syndrome Completed NCT00663897 Phase 4 lansoprazole;mosapride
8 Effects of Dexmedetomidine as an Adjunctive Analgesic Used in Continuous Thoracic Paravertebral Blocks for Post-thoracotomy Pain Syndrome Completed NCT02619513 Phase 4 Dexmedetomidine;Ropivacaine
9 A Prospective, Randomized, Double Blinded, Placebo Controlled Pilot Study Assessing the Effect of Perioperative Pregabalin on the Incidence of Chronic Post Thoracotomy Pain Syndrome Completed NCT00663962 Phase 4 Pregabalin;Placebo
10 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
11 Combined Platelet Rich Plasma Intra-articular Shoulder Injection and Stellate Ganglion Block. A New Technique for Management of Chronic Post-mastectomy Shoulder Pain Syndrome Completed NCT03586154 Phase 4 ketamine and bupivacaine injection
12 Prophylactic Administration of Vitamin C in Wrist Fractures; a Randomized Placebo Controlled Multicentre Dose-Finding Study of the Incidence of Complex Regional Pain Syndrome Completed NCT00296868 Phase 4 ascorbic acid (vitamin C) versus placebo
13 The Efficacy of Topical Thiocolchicoside in Cervical Myofascial Pain Syndrome: Triple-Arm, Single-Blind, Randomized, Prospective, Phase IV Clinical Study Completed NCT00272532 Phase 4 Thiocolchicoside
14 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
15 Gralise® for Spine Surgery Pain (GRASSP): A Partially Enriched, Placebo Controlled, Randomized, Double Blind, Cross-Over Trial of Gralise® for the Treatment of Post Laminectomy Pain Syndrome Completed NCT01764464 Phase 4 Gralise®;Placebo
16 Single Blinded, Randomized Control Trial of High Frequency Stimulation in Subjects With Precision® Spinal Cord Stimulator System to Assess Efficacy and Preferability in Back and Extremity Pain Relief Completed NCT02265848 Phase 4
17 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of Lidocaine Patch 5% Alone, Gabapentin Alone, And Lidocaine Patch 5% And Gabapentin In Combination For The Relief Of Pain In Patients With Diverse Peripheral Neuropathic Pain Conditions Completed NCT00904202 Phase 4 Placebo Capsules + Placebo Patch;Placebo capsules + Lidoderm®;Gabapentin + Placebo;Gabapentin + Lidoderm®;Gabapentin 300 mg capsules 1800 mg/day + placebo patch;Gabapentin 1800 mg/day + Lidoderm patch
18 Diagnostic Value of Comprehensive Cardiothoracic Dual Source CT for the Early Triage of Patients With Undifferentiated Acute Chest Pain Completed NCT01067456 Phase 4
19 Restore Claims Characterization Study Completed NCT00200122 Phase 4
20 Prevention of Persistent Pain and Opioid Use in Mothers - POMS Completed NCT03472521 Phase 4 Gabapentin;Placebo
21 Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. Recruiting NCT04704297 Phase 4 Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
22 GAG-therapy Efficacy Trial Solution for Bladder Pain Syndrome/ Interstitial Cystitis Recruiting NCT05518864 Phase 4
23 Evaluation of the Effect of Dextrose Prolotherapy on Pain and Function in Women With Myofascial Pain Syndrome Recruiting NCT04941118 Phase 4 Injection of dextrose, local anesthetic and saline to the myofascial trigger point;Local anesthetic and saline injection to the myofascial trigger point
24 IC PaIN Trial: Interstitial Cystitis Pain Improvement With Naltrexone, the Effect of Low Dose Naltrexone on Symptoms and Pain of Patients With Interstitial Cystitis/Painful Bladder Syndrome a Randomized Placebo-controlled Prospective Trial Recruiting NCT04313972 Phase 4 low-dose naltrexone;Placebo oral tablet
25 Peripheral Nerve Injections for the Treatment of Upper Extremity Complex Regional Pain Syndrome: A Feasibility Study for a Proposed Randomized Design Not yet recruiting NCT04744675 Phase 4 Triamcinolone Acetonide 40mg/mL;Saline Injection
26 Effectiveness 0f Sympathetic Plexus Block on Male Pelvic Pain (Prostatitis, Prostatodynia) Suspended NCT00194636 Phase 4
27 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
28 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
29 A Prospective, Open Label, Randomized, Parallel-group Investigation to Evaluate the Efficacy and Safety of Enoxaparin Versus no Enoxaparin in Subjects With Chest Pain Syndrome and no ECG or Biomarker Abnormalities Terminated NCT00518245 Phase 4 enoxaparin
30 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
31 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
32 Local Injection of Lidocaine Versus Ischemic Compression in Treatment of Woman With Chronic Pelvic Pain Caused by Abdominal Myofascial Pain Syndrome: Randomized Clinical Trial. Terminated NCT00628355 Phase 4 lidocaine
33 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4 Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide
34 A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment Withdrawn NCT00673972 Phase 4
35 Steroid Injection for the Treatment of Greater Trochanteric Pain Syndrome: A Randomized Controlled Trial Withdrawn NCT00863889 Phase 4 Depomedrol injection;Lidocaine, Marcaine
36 Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception in Men With Chronic Pain Syndrome Withdrawn NCT01689896 Phase 4 Testosterone Gel;Placebo Gel
37 Pilot Study: Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women, an Open Label Study With Dose Escalation Withdrawn NCT02981459 Phase 4 Mirabegron
38 Comparative Efficacy of Platelet Rich Plasma Injection and Dry Needling in Management of Trigger Points in Masseter Muscle in Myofascial Pain Syndrome Patients Unknown status NCT04286880 Phase 3
39 Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
40 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
41 An Analysis of Photoplethysmographic Signal in Diagnostic Lumbar Sympathetic Block for Complex Regional Pain Syndrome Unknown status NCT01134289 Phase 3
42 CREATE-1 Study: CRPS Treatment Evaluation 1 Study. A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of AXS-02 (Oral Zoledronate) Administered Orally to Subjects With Complex Regional Pain Syndrome Type I (CRPS-I) Unknown status NCT02504008 Phase 3 AXS-02 (oral zoledronate);Placebo
43 Surgical Treatment of Complex Regional Pain Syndrome Type II (CRPS II) by Regional Subcutaneous Venous Sympathectomy Unknown status NCT01392599 Phase 3
44 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period Unknown status NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
45 Effects of Proxelan Somministration in Patients With Chronic Prostatitis Cat. IIa NIH: Pilot Study Unknown status NCT03629769 Phase 3 Proxelan
46 Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial Completed NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
47 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
48 Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I Completed NCT00817128 Phase 2, Phase 3
49 Open-label Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS) Completed NCT02972359 Phase 3 Neridronic acid
50 A Multicenter, Double Blind, Randomised, Parallel Study to Assess Efficacy and Tolerability After Single Administration of Ketoprofen Lysine Salt 40 mg Granules vs Placebo in Subjects With Acute Pain Syndrome After Removal of Molar Teeth Completed NCT03836807 Phase 3 Ketoprofen

Search NIH Clinical Center for Paine Syndrome

Genetic Tests for Paine Syndrome

Anatomical Context for Paine Syndrome

Organs/tissues related to Paine Syndrome:

MalaCards : Dorsal Root Ganglion, Spinal Cord, Breast, Cortex, Brain, Prostate, Bone

Publications for Paine Syndrome

Articles related to Paine Syndrome:

(show top 50) (show all 14101)
# Title Authors PMID Year
1
X-chromosomal recessive microcephaly with epilepsy, spastic tetraplegia and absent abdominal reflexes. New variety of "Paine syndrome"? 62 57
4274173 1973
2
Conference report: International Workshop on the fragile X and X-linked mental retardation. 57
6369987 1984
3
Evaluation of familial biochemically determined mental retardation in children, with special reference to aminoaciduria. 57
14429829 1960
4
Perioperative transcutaneous electrical acupoint stimulation (pTEAS) in pain management in major spinal surgery patients. 41
36348477 2022
5
Predictive Models for Knee Pain in Middle-Aged and Elderly Individuals Based on Machine Learning Methods. 41
36199766 2022
6
Proposal and Efficacy of a Nurse-Led Pain Management Model for Neurointensive Care Based on the Precede-Proceed Model. 41
35979046 2022
7
Pathophysiology and Clinical Biomarkers in Interstitial Cystitis. 62
36424082 2023
8
Research progress and challenges of TRPV1 channel modulators as a prospective therapy for diabetic neuropathic pain. 62
36395649 2023
9
Trigeminal Neuralgia. 62
36404084 2023
10
Persistent Idiopathic Dentoalveolar Pain: Is It a Central Pain Disorder? 62
36404082 2023
11
Peroxinitrite and Malondialdehyde as Biomarkers for Overactive Bladder. 62
36474380 2022
12
Reduced mastication is a risk factor for Rome IV postprandial distress syndrome in patients investigated with upper endoscopy. 62
36244614 2022
13
Identifying female responders to proximal control exercises in patellofemoral pain syndrome: A clinical prediction rule. 62
36212592 2022
14
A postural program to reduce dynamic knee valgus during single-limb squatting in young athletes: a preliminary study. 62
35191290 2022
15
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Letter. 62
36129382 2022
16
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. Reply. 62
36129383 2022
17
A Diagnostic Prediction Model for Separating Juvenile Idiopathic Arthritis and Chronic Musculoskeletal Pain Syndrome. 62
35460700 2022
18
Efficacy of low-level laser therapy on pain, disability, pressure pain threshold, and range of motion in patients with myofascial neck pain syndrome: a systematic review and meta-analysis of randomized controlled trials. 62
35962884 2022
19
Efficacy and safety of selective serotonin re-uptake inhibitors for chronic prostatitis/chronic pelvic pain syndrome: A systematic review and network meta-analysis. 62
35739025 2022
20
[Electrotherapeutical stellate ganglion block on a patient with complex regional pain syndrome of the upper limb]. 62
36459205 2022
21
Personalised rehabilitation to improve return to work in patients with persistent spinal pain syndrome type II after spinal cord stimulation implantation: a study protocol for a 12-month randomised controlled trial-the OPERA study. 62
36471349 2022
22
Transvaginal Photobiomodulation Improves Pain in Women with Pelvic Muscle Tenderness and Interstitial Cystitis/Bladder Pain Syndrome: A Preliminary Observational Study. 62
36116559 2022
23
Predictors of Male Sexual Dysfunction in Urologic Chronic Pelvic Pain Syndrome (UCPPS), Other Chronic Pain Syndromes, and Healthy Controls in the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. 62
36180370 2022
24
Effect of electroacupuncture on inflammatory signal expression in local tissues of rats with chronic pelvic pain syndrome based on purinergic 2X7 receptor/NOD-like receptor pyrin domain-containing 3 signal pathway. 62
36378055 2022
25
Potential Role of Insulin-Like Growth Factors in Myofascial Pain Syndrome: A Narrative Review. 62
35067552 2022
26
Successful Multimodal Treatment for Complex Regional Pain Syndrome in an Adolescent with Acute Lymphoblastic Leukemia: A Case Report. 62
34936831 2022
27
Autoantibodies from patients with complex regional pain syndrome induce pro-inflammatory effects and functional disturbances on endothelial cells in vitro. 62
35384930 2022
28
Nociception level index variations in patients with complex regional pain syndrome: a pilot study. 62
35260985 2022
29
Vaginal Hormone Therapy for Conditions of the Lower Urinary Tract. 62
36454371 2022
30
External snapping hip syndrome is associated with an increased femoral offset. 62
34550475 2022
31
[Less invasive turn-down flap tendinoplasty in chronic Achilles tendon rupture]. 62
36036248 2022
32
The epidemiology of dystonia: the Hannover epidemiology study. 62
35948800 2022
33
Connective tissue graft versus xenogeneic collagen matrix for soft tissue augmentation at implant sites: a randomized-controlled clinical trial. 62
36029335 2022
34
Centralized nociplastic pain causing fibromyalgia: an emperor with no cloths? 62
36239845 2022
35
Chronic Pain Considerations in Patients with Cardiovascular Disease. 62
36328629 2022
36
[Surgical treatment of calcifying insertional Achilles tendinopathy via a lateral approach]. 62
36342529 2022
37
Techniques for Safe Removal of Spinal Cord Stimulation Paddle Leads. 62
36227247 2022
38
Diagnosis and treatment of pudendal and inferior cluneal nerve entrapment syndrome: a narrative review. 62
36074049 2022
39
Endoscopic treatment of gluteus medius tendon tear. 62
36075568 2022
40
Neuromodulation for Management of Chronic Pelvic Pain: A Comprehensive Review. 62
36109459 2022
41
Effect of CYP2C9, PTGS-1 and PTGS-2 gene polymorphisms on the efficiency and safety of postoperative analgesia with ketoprofen. 62
35705023 2022
42
Intravenous Lidocaine in Chronic Neuropathic Pain: A Systematic Review. 62
36288104 2022
43
The Language of Pain: Is There a Relationship Between Metaphor Use and Adjustment to Chronic Pain? 62
33729513 2022
44
Long-term Outcomes in Use of Opioids, Nonpharmacologic Pain Interventions, and Total Costs of Spinal Cord Stimulators Compared With Conventional Medical Therapy for Chronic Pain. 62
36441532 2022
45
The first-generation anatomical medial meniscus prosthesis led to unsatisfactory results: a first-in-human study. 62
36336744 2022
46
A Comparison Between Rome III and Rome IV Criteria in Children with Chronic Abdominal Pain: A Prospective Observational Cohort Study. 62
35946891 2022
47
Coronary microvascular dysfunction affects left ventricular global longitudinal strain response to dipyridamole stress echocardiography: a pilot study. 62
36380229 2022
48
A novel distractor-assisted reduction combined with the sinus tarsi approach for joint depression-type calcaneal fractures. 62
36370163 2022
49
Natural History of Degenerative Hip Abductor Tendon Lesions. 62
36412545 2022
50
Prevalence and associated risk factors of tinnitus among adult Palestinians: a cross-sectional study. 62
36450754 2022

Variations for Paine Syndrome

ClinVar genetic disease variations for Paine Syndrome:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HFE NM_000410.4(HFE):c.845G>A (p.Cys282Tyr) SNV Pathogenic
9 rs1800562 GRCh37: 6:26093141-26093141
GRCh38: 6:26092913-26092913
2 PTPRQ NM_001145026.2(PTPRQ):c.6475C>T (p.Arg2159Ter) SNV Pathogenic
523416 rs1445287184 GRCh37: 12:81064144-81064144
GRCh38: 12:80670365-80670365
3 COL5A1 NM_000093.5(COL5A1):c.608G>T (p.Gly203Val) SNV Likely Pathogenic
523328 rs1554781700 GRCh37: 9:137593133-137593133
GRCh38: 9:134701287-134701287
4 OAT NM_000274.4(OAT):c.875A>G (p.Lys292Arg) SNV Likely Pathogenic
374146 rs1057518927 GRCh37: 10:126091521-126091521
GRCh38: 10:124402952-124402952
5 SCN4A NM_000334.4(SCN4A):c.1333G>T (p.Val445Leu) SNV Likely Pathogenic
373945 rs121908552 GRCh37: 17:62041947-62041947
GRCh38: 17:63964587-63964587
6 GJB1 NM_000166.6(GJB1):c.109G>T (p.Val37Leu) SNV Likely Pathogenic
374173 rs1057518946 GRCh37: X:70443666-70443666
GRCh38: X:71223816-71223816
7 SELENON NM_020451.3(SELENON):c.482G>A (p.Arg161Gln) SNV Uncertain Significance
373919 rs765749301 GRCh37: 1:26131711-26131711
GRCh38: 1:25805220-25805220
8 KIF1B NM_001365951.3(KIF1B):c.2611G>A (p.Glu871Lys) SNV Uncertain Significance
373920 rs763122049 GRCh37: 1:10384889-10384889
GRCh38: 1:10324831-10324831
9 MAP2K2 NM_030662.4(MAP2K2):c.514A>G (p.Lys172Glu) SNV Uncertain Significance
523536 rs1413580671 GRCh37: 19:4102388-4102388
GRCh38: 19:4102390-4102390

Expression for Paine Syndrome

Search GEO for disease gene expression data for Paine Syndrome.

Pathways for Paine Syndrome

Pathways related to Paine Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.56 SCN9A SCN4A SCN3A SCN11A SCN10A
2
Show member pathways
12.39 SCN9A SCN4A SCN3A SCN11A SCN10A
3
Show member pathways
12.39 TAC1 SCN9A SCN4A SCN3A SCN11A SCN10A
4 12.23 SCN9A SCN4A SCN11A SCN10A OPRM1 NGF
5
Show member pathways
11.93 SCN9A SCN4A SCN3A SCN11A SCN10A
6 10.89 SCN9A SCN4A SCN3A SCN11A SCN10A
7 10.51 SCN9A SCN4A SCN3A SCN11A SCN10A
8 9.85 TRPV1 TRPA1

GO Terms for Paine Syndrome

Cellular components related to Paine Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 membrane GO:0016021 10.48 TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
2 membrane GO:0016020 10.48 TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
3 plasma membrane GO:0005887 10.34 HFE OPRM1 P2RX3 SCN4A SCN9A TRPA1
4 plasma membrane GO:0005886 10.34 HFE OPRM1 P2RX3 SCN4A SCN9A TRPA1
5 neuronal cell body GO:0043025 9.97 TRPV1 TAC1 SCN11A PNOC P2RX3 GAL
6 voltage-gated sodium channel complex GO:0001518 9.65 SCN10A SCN11A SCN3A SCN4A SCN9A
7 stereocilium bundle GO:0032421 9.58 TRPA1 PTPRQ
8 axon GO:0030424 9.58 TAC1 SCN9A SCN4A SCN3A SCN11A SCN10A
9 obsolete integral component of presynaptic membrane GO:0099056 9.43 SCN10A P2RX3 OPRM1

Biological processes related to Paine Syndrome according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 regulation of monoatomic ion transmembrane transport GO:0034765 10.27 SCN10A SCN11A SCN3A SCN4A SCN9A
2 sodium ion transmembrane transport GO:0035725 10.25 SCN9A SCN4A SCN3A SCN11A SCN10A
3 neuropeptide signaling pathway GO:0007218 10.24 CALCA GAL OPRM1 PNOC TAC1
4 sodium ion transport GO:0006814 10.18 SCN9A SCN4A SCN3A SCN11A SCN10A
5 positive regulation of cytosolic calcium ion concentration GO:0007204 10.17 TRPV1 TAC1 OPRM1 CALCA
6 transmembrane transport GO:0055085 10.16 GJB1 SCN10A SCN11A SCN3A SCN4A SCN9A
7 calcium ion transmembrane transport GO:0070588 10.15 OPRM1 SCN11A TRPA1 TRPV1
8 response to cold GO:0009409 10.09 TRPA1 SCN9A P2RX3
9 cellular response to nerve growth factor stimulus GO:1990090 10.07 TRPV1 TAC1 CALCA
10 sensory perception GO:0007600 10.03 SCN10A PNOC OPRM1
11 response to heat GO:0009408 10.03 CALCA P2RX3 SCN11A SCN9A TRPV1
12 monoatomic ion transport GO:0006811 9.96 TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A
13 response to pain GO:0048265 9.95 TRPV1 TRPA1 TAC1 CALCA
14 detection of temperature stimulus involved in sensory perception of pain GO:0050965 9.93 TRPV1 SCN9A SCN11A CALCA
15 thermoception GO:0050955 9.9 TRPV1 TRPA1
16 sensory perception of pain GO:0019233 9.9 OPRM1 SCN10A SCN9A TAC1 TRPA1 TRPV1
17 monoatomic cation transmembrane transport GO:0098655 9.89 SCN9A SCN3A SCN11A SCN10A P2RX3
18 detection of chemical stimulus involved in sensory perception of pain GO:0050968 9.88 TRPV1 TRPA1
19 behavioral response to formalin induced pain GO:0061368 9.88 SCN9A SCN11A P2RX3
20 monoatomic ion transmembrane transport GO:0034220 9.87 P2RX3 SCN10A SCN11A SCN3A SCN9A TRPA1
21 urinary bladder smooth muscle contraction GO:0014832 9.79 TRPV1 P2RX3
22 behavioral response to pain GO:0048266 9.77 TRPV1 SCN9A SCN3A P2RX3
23 membrane depolarization during action potential GO:0086010 9.65 SCN9A SCN4A SCN3A SCN11A SCN10A
24 calcitonin gene-related peptide receptor signaling pathway GO:1990408 9.58 SCN11A CALCA
25 neuronal action potential GO:0019228 9.4 SCN9A SCN4A SCN3A SCN11A SCN10A P2RX3

Molecular functions related to Paine Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 voltage-gated monoatomic ion channel activity GO:0005244 9.97 SCN9A SCN4A SCN3A SCN11A SCN10A
2 voltage-gated sodium channel activity GO:0005248 9.96 SCN10A SCN11A SCN3A SCN4A SCN9A
3 calcium-release channel activity GO:0015278 9.67 TRPV1 TRPA1
4 sodium channel activity GO:0005272 9.55 SCN9A SCN4A SCN3A SCN11A SCN10A
5 monoatomic cation channel activity GO:0005261 9.43 TRPV1 SCN9A SCN4A SCN3A SCN11A SCN10A
6 monoatomic ion channel activity GO:0005216 9.28 TRPV1 TRPA1 SCN9A SCN4A SCN3A SCN11A

Sources for Paine Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....